How big is Arrowhead Pharmaceuticals, Inc.?

As of Jun 18, Arrowhead Pharmaceuticals, Inc. has a market capitalization of $2.14 billion, with recent net sales of $545.21 million and a net profit of -$154.68 million for the latest four quarters.

Market Cap: As of Jun 18, Arrowhead Pharmaceuticals, Inc. has a market capitalization of 2,140.56 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, Arrowhead Pharmaceuticals reported net sales of 545.21 million and a net profit of -154.68 million.<BR><BR>Balance Sheet Snapshot: As of September 2024, the company reported shareholder's funds of 185.44 million and total assets of 1,139.80 million.

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals, Inc. develops gene-silencing medicines for intractable diseases and is classified as a small-cap biotechnology company. As of March 2025, it reported net sales of $543 million and a net profit of $368 million, with a market cap of approximately $2.14 billion.

Overview: <BR>Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 543 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 368 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,140.56 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.68 <BR>Return on Equity: -22.64% <BR>Price to Book: 3.13<BR><BR>Contact Details: <BR>Address: 177 E Colorado Blvd, Suite 700, PASADENA CA: 91105 <BR>Tel: ['1 626 6964702', '1 626 3043400'] <BR>Fax: 1 626 3043401 <BR>Website: http://arrowheadpharma.com/

Who are in the management team of Arrowhead Pharmaceuticals, Inc.?

As of March 2022, the management team of Arrowhead Pharmaceuticals, Inc. includes Dr. Douglass Given (Chairman), Dr. Christopher Anzalone (CEO), Dr. Michael Perry (Lead Independent Director), and several other independent directors. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Arrowhead Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Douglass Given, Chairman of the Board<BR>- Dr. Christopher Anzalone, President, Chief Executive Officer, and Director<BR>- Dr. Michael Perry, Lead Independent Director<BR>- Dr. Marianne De Backer, Independent Director<BR>- Dr. Mauro Ferrari, Independent Director<BR>- Mr. Oye Olukotun, Independent Director<BR>- Mr. William Waddill, Independent Director<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Should I buy, sell or hold Arrowhead Pharmaceuticals, Inc.?

Is Arrowhead Pharmaceuticals, Inc. overvalued or undervalued?

As of August 5, 2020, Arrowhead Pharmaceuticals, Inc. has a risky valuation grade due to being overvalued with poor financial metrics compared to peers, despite a recent short-term stock performance that outpaced the S&P 500.

As of 5 August 2020, the valuation grade for Arrowhead Pharmaceuticals, Inc. moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued given its current financial metrics, including a Price to Book Value of 3.40, an EV to EBIT of -15.66, and an EV to EBITDA of -19.06, which suggest significant losses relative to its enterprise value. <BR><BR>In comparison to its peers, Arrowhead's valuation ratios are notably weaker; for instance, BridgeBio Pharma, Inc. has an EV to EBITDA of -19.73, while CRISPR Therapeutics AG has a more favorable EV to EBITDA of -7.37. Additionally, Arrowhead's recent stock performance has outpaced the S&P 500 in the short term, with a 1-month return of 58.26% compared to the S&P 500's 2.33%, but its long-term performance remains concerning with a 5-year return of -26.89% versus the S&P 500's 96.61%.

Is Arrowhead Pharmaceuticals, Inc. technically bullish or bearish?

As of August 28, 2025, Arrowhead Pharmaceuticals has a bullish technical trend, supported by strong indicators like the weekly MACD and Bollinger Bands, and has outperformed the S&P 500 with a 58.26% return over the past month.

As of 28 August 2025, the technical trend for Arrowhead Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD and Bollinger Bands are both bullish, supporting a strong upward momentum. Daily moving averages also indicate bullish sentiment. The monthly MACD and KST are mildly bullish, while the Dow Theory shows a mildly bullish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, Arrowhead Pharmaceuticals has significantly outperformed the S&P 500 over the past month with a return of 58.26% compared to the S&P 500's 2.33%, and it has also shown strong year-to-date performance at 67.61% versus 12.22%. Overall, the current technical stance is bullish with strong indicators supporting this outlook.